FDA Brief

Warning letters Drugs

FDA warning letter to

ABR Laboratory LLC

High riskIssued Feb 10, 2025Posted Feb 18, 2025Center for Drug Evaluation and Research (CDER)

FDA warned ABR Laboratory, a contract drug testing lab, that unverified microbial test methods and missed investigations made tested drugs adulterated.

What happened

FDA inspected ABR Laboratory, a contract testing laboratory in Hollywood, FL, from September 9 to 13, 2024. FDA found that ABR's microbial test method for over-the-counter (OTC) drug products was not shown to be equivalent to or better than the United States Pharmacopeia (USP) method and that method suitability was not performed for certain products, including a children’s product. FDA also found that ABR did not investigate out-of-range temperature and humidity readings, including a 2–8°C refrigerator that reached 17.4°C for more than 24 hours while holding reference microorganisms.

What FDA found

  1. ABR did not establish and document that its microbial test method was accurate, sensitive, specific, and reproducible; the method was not verified as equivalent to or better than the USP method.

    21 CFR 211.165(e)
  2. ABR did not perform method suitability testing for certain OTC drug products, including a children’s product.

    21 CFR 211.165(e)
  3. ABR did not investigate out-of-range temperature and humidity readings, including a refrigerator holding reference microorganisms that was above its 2–8°C range for more than 24 hours and reached 17.4°C.

    21 CFR 211.192

What FDA wants

FDA tells ABR to correct the violations promptly and to send FDA’s drug center (CDER) an independent assessment of its laboratory and investigation systems, a retrospective review with re-testing and customer notification plans, updated method-suitability procedures, and training records. The letter does not state a specific response deadline.

Who should pay attention

  • drug companies that use ABR as a contract testing lab
  • brands selling OTC drugs tested by ABR
  • quality teams relying on contract lab microbial results

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Almon Healthcare Private Limited

    Almon Healthcare, an Indian active pharmaceutical ingredient (API) maker, knowingly used mislabeled, untested raw material and shipped affected drugs to the U.S.

    High risk
  2. Spa De Soleil, Inc.

    FDA cites Spa De Soleil for CGMP violations in OTC topical drugs, including water system failures and missing component identity testing.

    High risk
  3. Harbin Jixianglong Biotech Co., Ltd.

    FDA warned Harbin Jixianglong Biotech over CGMP (manufacturing quality rules) failures and misbranded relabeled semaglutide API with false manufacturer labels and missing drug listings.

    High risk
  4. Active Cosmetics Manufacturing Inc.

    FDA cited Active Cosmetics Manufacturing for releasing topical OTC drugs after microbial contamination without thorough investigations.

    High risk